An Acceptable Incidence of Infusion Site Reactions after Subcutaneous Bortezomib Administration in the Upper Arm in Japanese Patients with Multiple Myeloma

被引：1
|
作者：
Ohgiya, Daisuke [1 ]
Tsuchiya, Takahide [1 ]
Suyama, Takahiro [1 ]
Watanabe, Shigeki [1 ]
Numata, Hiroki [2 ]
Tsuboi, Kosuke [2 ]
Sasao, Tamotsu [2 ]
机构：
[1] Ebina Gen Hosp, Dept Hematol, Ebina, Kanagawa 2430433, Japan
[2] Ozawa Hosp, Dept Hematol, Odawara, Kanagawa, Japan
来源：
ACTA HAEMATOLOGICA | 2015年 / 133卷 / 01期
关键词：
D O I：
10.1159/000362587
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：29 / 30
页数：2
相关论文
共 44 条
  • [31] Self-Administration Of Subcutaneous Bortezomib At Home In Cancer Patients With Multiple Myeloma. Patients And Health Professionals Perspectives And Organizational Aspects, In A Mixed Methods Study
    Kirkegaard, Jannie
    INTERNATIONAL JOURNAL OF INTEGRATED CARE, 2022, 22
  • [32] Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study
    Horvath, Noemi
    Spencer, Andrew
    Kenealy, Melita
    Joshua, Douglas
    Campbell, Philip J.
    Lee, Je-Jung
    Hou, Jian
    Qiu, Lugui
    Kalff, Anna
    Khong, Tiffany
    Londhe, Anil
    Siggins, Sarah
    van Kooten Losio, Maximiliano
    Eisbacher, Michael
    Prince, H. Miles
    LEUKEMIA & LYMPHOMA, 2019, 60 (09) : 2122 - 2133
  • [33] COMPARISON OF RESPONSE DURATION (RPD) AFTER THALIDOMIDE, BORTEZOMIB AND LENALIDOMIDE ADMINISTRATION TO MULTIPLE MYELOMA (MM) PATIENTS; A SINGLE CENTER EXPERIENCE
    Kyrtsonis, M. C.
    Nikolaou, E.
    Maltezas, D.
    Koulieris, E.
    Iliakis, T.
    Sarris, K.
    Vyniou, E.
    Vardounioti, I.
    Efthymiou, A.
    Bitsani, K.
    Karali, V.
    Pessach, I.
    Bartzis, V.
    Tzenou, T.
    Dimou, M.
    Vassilakopoulos, T.
    Angelopoulou, M.
    Tsaftaridis, P.
    Panayiotidis, P.
    HAEMATOLOGICA, 2014, 99 : 646 - 646
  • [34] An evaluation of efficiency, safety, tolerability, patient satisfaction, and preference of subcutaneous (SQ) versus intravenous (IV) bortezomib (BTZ) administration in patients with multiple myeloma (MM).
    Barbee, Meagan Spencer
    Wilson, Nicole Maire
    Harvey, R. Donald
    McKibbin, Trevor
    Lonial, Sagar
    Kaufman, Jonathan L.
    Shah, Katherine Sanvidge
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [35] Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple Myeloma
    Quach, Hang
    Parmar, Gurdeep
    Mateos, Maria-Victoria
    Ailawadhi, Sikander
    Leleu, Xavier
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (06): : 358 - 363
  • [36] Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients
    Shuichiro Takashima
    Toshihiro Miyamoto
    Masanori Kadowaki
    Yoshikiyo Ito
    Takatoshi Aoki
    Ken Takase
    Takahiro Shima
    Goichi Yoshimoto
    Koji Kato
    Tsuyoshi Muta
    Motoaki Shiratsuchi
    Katsuto Takenaka
    Hiromi Iwasaki
    Takanori Teshima
    Tomohiko Kamimura
    Koichi Akashi
    International Journal of Hematology, 2014, 100 : 159 - 164
  • [37] Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients
    Takashima, Shuichiro
    Miyamoto, Toshihiro
    Kadowaki, Masanori
    Ito, Yoshikiyo
    Aoki, Takatoshi
    Takase, Ken
    Shima, Takahiro
    Yoshimoto, Goichi
    Kato, Koji
    Muta, Tsuyoshi
    Shiratsuchi, Motoaki
    Takenaka, Katsuto
    Iwasaki, Hiromi
    Teshima, Takanori
    Kamimura, Tomohiko
    Akashi, Koichi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2014, 100 (02) : 159 - 164
  • [38] Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
    Neben, Kai
    Lokhorst, Henk M.
    Jauch, Anna
    Bertsch, Uta
    Hielscher, Thomas
    van der Holt, Bronno
    Salwender, Hans
    Blau, Igor W.
    Weisel, Katja
    Pfreundschuh, Michael
    Scheid, Christof
    Duehrsen, Ulrich
    Lindemann, Walter
    Schmidt-Wolf, Ingo G. H.
    Peter, Norma
    Teschendorf, Christian
    Martin, Hans
    Haenel, Mathias
    Derigs, Hans G.
    Raab, Marc S.
    Ho, Anthony D.
    van de Velde, Helgi
    Hose, Dirk
    Sonneveld, Pieter
    Goldschmidt, Hartmut
    BLOOD, 2012, 119 (04) : 940 - 948
  • [39] Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study (vol 12, pg 431, 2011)
    Moreau, P.
    Pylypenko, H.
    Grosicki, S.
    LANCET ONCOLOGY, 2011, 12 (06): : 522 - 522
  • [40] Lack of Notable Skin Reactions from a Novel Levodopa/Carbidopa Prodrug after 10 Days of Repeated 24-Hour Continuous Subcutaneous Infusion at the Same Administration Site
    Facheris, M.
    Qi, X.
    Locke, C.
    Rosebraugh, M.
    Benesh, J.
    MOVEMENT DISORDERS, 2019, 34 : S39 - S39
12345